panaxadiol has been researched along with Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H; Li, X; Sun, B; Wang, Z; Xiao, S; Xu, L; Zhang, X; Zhao, Y | 1 |
| Cho, SJ; Choi, JS; Kim, HY; Lee, SK; Lee, WH; Park, BD; Park, JH; Surh, YJ | 1 |
2 other study(ies) available for panaxadiol and Breast Cancer
| Article | Year |
|---|---|
Panaxadiol as a major metabolite of AD-1 can significantly inhibit the proliferation and migration of breast cancer cells: In vitro and in vivo study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ginsenosides; Humans; Molecular Structure; Structure-Activity Relationship | 2021 |
Potentiation of etoposide-induced apoptosis in HeLa cells by co-treatment with KG-135, a quality-controlled standardized ginsenoside formulation.
Topics: Androstadienes; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Etoposide; Female; Ginsenosides; HeLa Cells; Humans; Korea; Liver Neoplasms; Medicine, East Asian Traditional; Membrane Potentials; Mitochondria; Mycotoxins; Phosphoserine; Stomach Neoplasms; Wortmannin | 2010 |